Latest Breaking News On - Human immunology biosciences inc - Page 1 : comparemela.com

Asahi Kasei to Buy Swedish Biotech for Rare Disease Drug

Asahi Kasei to Buy Swedish Biotech for Rare Disease Drug
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Stockholm
Sweden
Swedish
Asahi-kasei
Natsuko-katsuki
Van-lanschot-kempen
Health-partners
Mariana-oncology-inc
Human-immunology-biosciences-inc
Novartis
Asahi-kasei-corp
Biogen-inc

HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients

82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n

Stockholm
Sweden
United-states
Macau
China
Hong-kong
Vienna
Wien
Austria
Taiwan
Georg-bo
Uptal-patel

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Stockholm
Sweden
China
Vienna
Wien
Austria
Macau
United-states
Hong-kong
Taiwan
Caroline-fry
Morgan-warners

HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress

HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Taiwan
United-states
Hong-kong
Stockholm
Sweden
Macau
China
Japan
Germany
Uptal-patel
Morgan-warners
Caroline-fry

Rare disease deal: Biogen buys Hibio for $1.15B up front

In a deal worth up to $1.8 billion, Biogen Inc. is buying Human Immunology Biosciences Inc. (Hibio), bolstering its late-stage immune-disease treatment portfolio and diversifying its pipeline. The massive amount comprises $1.15 billion up front and as much as $650 in potential milestone payments.

Biogen-inc
Human-immunology-biosciences-inc
Human-immunology-biosciences